Blood Samples From Patients With Cancer Treated on a Clinical Trial to Control Nausea and Vomiting During Donor Stem Cell Transplant
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about nausea and vomiting caused by cancer treatment.
PURPOSE: This laboratory study is looking at blood samples from patients with cancer who were treated on a clinical trial to control nausea and vomiting during donor stem cell transplant.
Chronic Myeloproliferative Disorders
Gestational Trophoblastic Tumor
Multiple Myeloma and Plasma Cell Neoplasm
Nausea and Vomiting
Testicular Germ Cell Tumor
Other: immunoenzyme technique
Other: laboratory biomarker analysis
Other: medical chart review
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Substance P Follow-up to a Pilot Study of Aprepitant vs Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplantation|
- Average, median, and mode for substance P levels at different times [ Designated as safety issue: No ]
- Correlation of substance P levels with patient response (emesis or not) [ Designated as safety issue: No ]
|Study Start Date:||August 2008|
|Study Completion Date:||October 2009|
|Primary Completion Date:||August 2009 (Final data collection date for primary outcome measure)|
- To compare the amount of substance P in serum samples from patients with cancer treated with busulfan/cyclophosphamide or cyclophosphamide/total body irradiation conditioning regimens prior to undergoing allogeneic hematopoietic stem cell transplantation.
- To assess the changes in substance P over time to see if there is an optimal time shown by this physiologic correlate to discontinue substance P blockade after the chemotherapy regimen is completed in these patients.
OUTLINE: Previously collected serum samples are analyzed by enzyme immunoassay for changes in substance P levels.
Patients' medical records are reviewed for demographic information, past history, and course of treatment.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00900068
|United States, Oregon|
|OHSU Knight Cancer Institute|
|Portland, Oregon, United States, 97239-3098|
|Principal Investigator:||Joseph Bubalo, PharmD, BCPS, BCOP||OHSU Knight Cancer Institute|